

We claim:

1. A pharmaceutical composition comprising a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients wherein said treatment extends the overall survival and/or the progression free survival of said patients.
2. A pharmaceutical composition comprising an anti-CD19 antibody for use in the treatment of hematological cancer patients wherein said anti-CD19 antibody is administered in combination with lenalidomide and wherein said treatment extends the overall survival and/or the progression free survival of said patients.
3. A pharmaceutical composition comprising lenalidomide for use in the treatment of hematological cancer patients wherein lenalidomide is administered in combination with an anti-CD19 antibody and wherein said treatment extends the overall survival and/or the progression free survival of said patients.
4. The pharmaceutical composition of one of the claims 1-3 for use in the treatment of hematological cancer patients wherein said hematological cancer patients have received one line of previous treatment and wherein the 12-months overall survival rate is 80% or more.
5. The pharmaceutical composition of claim 4 for use in the treatment of hematological cancer patients wherein the 12-months progression free survival is 55% or more.
6. The pharmaceutical composition of one of the claims 1-3 for use in the treatment of hematological cancer patients wherein said hematological cancer patients have received two or more lines of previous treatment and wherein the 12-months overall survival rate is 55% or more.
7. The pharmaceutical composition of claim 6 for use in the treatment of hematological cancer patients wherein the 12-months progression free survival is 35% or more.
8. The pharmaceutical composition of one of the preceding claims for use in the treatment of hematological cancer patients wherein said hematological cancer patients have non-Hodgkin's lymphoma selected from the group of follicular lymphoma, small lymphocytic

- lymphoma, mucosa-associated lymphoid tissue, marginal zone lymphoma, diffuse large B cell lymphoma, Burkitt's lymphoma and mantle cell lymphoma.
9. The pharmaceutical composition of one of the claims 1-3 for use in the treatment of hematological cancer patients wherein said hematological cancer patients have a germinal center B-cell type (GCB) DLBCL and wherein the 12-months overall survival rate is 60% or more.
 10. The pharmaceutical composition of claim 9 for use in the treatment of hematological cancer patients wherein the 12-months progression free survival is 35% or more.
 11. The pharmaceutical composition of one of the claims 1-3 for use in the treatment of hematological cancer patients wherein said hematological cancer patients have a non-germinal center B-cell type (non-GCB) DLBCL and wherein the 12-months overall survival rate is 80% or more.
 12. The pharmaceutical composition of claim 11 for use in the treatment of hematological cancer patients wherein the 12-months progression free survival is 70% or more.
 13. The pharmaceutical composition of one of the claims 1 to 12 for use in the treatment of hematological cancer patients wherein said anti-CD19 antibody comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
 14. The pharmaceutical composition of one of the claims 1 to 13 for use in the treatment of hematological cancer patients wherein said anti-CD19 antibody comprises a variable heavy chain of the sequence
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGT
KYNEKFQGRVTISSDKSISTAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWGQGTL
VTVSS (SEQ ID NO: 7)
and a variable light chain of the sequence

DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL
NSGVPDRFSGSGSGTEFTLTISSELPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID
NO: 8).

15. The pharmaceutical composition of one of the claims 1 to 14 for use in the treatment of hematological cancer patients wherein said anti-CD19 antibody comprises a heavy chain having the sequence

EVQLVESGGGLVHPGGLSLKSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGT
KYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGGQTL
VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
AVLQSSGLYSLSSVVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCP
APPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAK
TKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKALPAAPEEKTISKTKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPMLDSDGSF
FLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 11)

and a light chain having the sequence

DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL
NSGVPDRFSGSGSGTEFTLTISSELPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVAAPS
VFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 12)

16. The pharmaceutical composition of one of the preceding claims for use according to one of the preceding claims wherein said anti-CD19 antibody is administered at least bi-weekly at an amount of 12 mg/kg per dose and wherein lenalidomide is administered daily at an amount of 25mg.